Sensus Healthcare (NASDAQ:SRTS) Upgraded to Hold at Wall Street Zen

Sensus Healthcare (NASDAQ:SRTS) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

A number of other analysts also recently issued reports on the company. Maxim Group decreased their target price on Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Lake Street Capital reduced their price target on Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Sensus Healthcare in a research report on Friday, April 4th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $11.67.

Sensus Healthcare Trading Down 3.2%

NASDAQ SRTS opened at $4.81 on Friday. Sensus Healthcare has a 12 month low of $4.01 and a 12 month high of $9.33. The business’s 50-day moving average price is $4.66 and its two-hundred day moving average price is $5.76. The firm has a market capitalization of $79.10 million, a PE ratio of 12.03 and a beta of 1.32.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.20). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. The firm had revenue of $8.34 million during the quarter, compared to the consensus estimate of $7.23 million. As a group, analysts forecast that Sensus Healthcare will post 0.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in SRTS. Acadian Asset Management LLC boosted its stake in Sensus Healthcare by 35.3% during the 1st quarter. Acadian Asset Management LLC now owns 470,713 shares of the company’s stock valued at $2,225,000 after purchasing an additional 122,746 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Sensus Healthcare by 5.3% in the 4th quarter. Renaissance Technologies LLC now owns 430,934 shares of the company’s stock worth $2,982,000 after purchasing an additional 21,600 shares during the period. Dimensional Fund Advisors LP raised its holdings in Sensus Healthcare by 30.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 378,568 shares of the company’s stock valued at $2,620,000 after acquiring an additional 88,953 shares during the period. Arrowstreet Capital Limited Partnership raised its holdings in Sensus Healthcare by 81.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 150,150 shares of the company’s stock valued at $1,039,000 after acquiring an additional 67,269 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Sensus Healthcare by 3.9% during the first quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company’s stock valued at $672,000 after acquiring an additional 5,289 shares during the period. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.